Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.
about
Improving the clinical impact of biomaterials in cancer immunotherapy.Engineering opportunities in cancer immunotherapyNanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and ImmunotherapyThe impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug deliveryCancer targeted therapeutics: From molecules to drug delivery vehicles.Nano-palladium is a cellular catalyst for in vivo chemistryTailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond.Drug delivery by erythrocytes: "Primum non nocere".Cell-Based Biohybrid Drug Delivery Systems: The Best of the Synthetic and Natural Worlds.Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells.Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites.Delivering safer immunotherapies for cancer.Engineering challenges for brain tumor immunotherapy.MYC Modulation around the CDK2/p27/SKP2 AxisEnhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors.A melanin-mediated cancer immunotherapy patch.Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.Macrophages as an active tumour-targeting carrier of SN38-nanoparticles for cancer therapy.Engineering and physical sciences in oncology: challenges and opportunities.Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy.Exploiting homing abilities of cell carriers: Targeted delivery of nanoparticles for cancer therapy.Improving Vaccine and Immunotherapy Design Using Biomaterials.Immunoengineering with biomaterials for enhanced cancer immunotherapy.Cell Membrane Bioconjugation and Membrane-Derived Nanomaterials for Immunotherapy.Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges.Nanoparticles-Emerging Potential for Managing Leukemia and Lymphoma.Applications of nanoparticle systems in drug delivery technology.Neutrophil-mediated delivery of nanotherapeutics across blood vessel barrier.Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.Progress and challenges towards targeted delivery of cancer therapeutics.Prescription for a pharmacyte.Engineering nanoparticles to overcome barriers to immunotherapy.Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy.Remote Control of Mammalian Cells with Heat-Triggered Gene Switches and Photothermal Pulse Trains.Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
P2860
Q26766267-7AF73F6C-7D7E-44EF-999A-687E756A17E1Q26776373-0140AAA1-6A15-4612-B5AB-64C443A61BFAQ26782566-CF75A042-5D98-4FCD-8133-21FF381C87D0Q28085280-B280FA09-B7CE-48E1-8DB0-F6E885425328Q33887986-278D69FD-E6D0-435E-B212-3CE0E966A58BQ33903811-75F9D558-5326-48B7-9358-22BA101C54F8Q38677432-29C70172-EB31-4FF9-B0D8-9FBDD6AF858AQ38912004-9279D2D9-10DC-4851-9ECB-C1931BE245DAQ38972974-D4E7374A-33C6-42D2-ACAF-ED7C030EE678Q39011174-7B4E443A-61F5-4E98-87A0-B681DCAC2EF8Q39031369-8A21D471-75E0-4CA1-A398-559DDE171322Q39110669-AF7F1F90-1160-4BEF-BC03-897308FD65C2Q39159035-AF182712-9564-438D-8F6E-807891B031C5Q39330984-49CCB47E-D13C-4D1E-91AE-712CCC0EF137Q39381281-39B230F4-7661-4A92-A4E3-68CAF1E43F68Q39406924-75A246ED-10FE-4DC8-91B8-B0251EDC27F7Q42380337-88B59D2D-05FC-4A9D-818B-214DCB78E1DAQ44876957-004CB42D-AFB6-4293-BD18-E8E07846EC07Q46366459-6FFDF978-48CA-4E6F-8D96-B61C4B209A9AQ47132997-9F7F5EFF-B472-41E6-83C3-29D913BE17B7Q47240231-AF4F0BC4-79E5-4097-AAED-5706A7CD74F5Q47244877-7B2C5495-00E5-4B67-9F97-95C3FDB9D39BQ47342244-5CC438AC-AAFD-45AE-927A-47B53B25E0CAQ47568478-5734BA05-9D8D-4568-9593-306E2C4B0929Q47676665-65999D24-F8F6-45F4-ADAF-3AEACE241375Q47732542-33873EDC-13FD-442B-AA5A-83E8EA5EC9E4Q47738496-E4A5CD8D-5B19-47A4-A685-B7FC93A9F09EQ47940254-9DF4E557-830C-4FF2-BE8C-EBDC0AD5566CQ48540669-328F090B-BC75-490F-AFCA-15EAEB2710DAQ49197456-B0EE05B4-DF0E-4852-9A29-B8EE7DD0F5AFQ50026117-E1F40BAF-663C-47B6-A3D4-18673E62CF0CQ50426810-A8DDD683-B222-4DD5-A855-0DBFBA4F7198Q52590993-0816C3BA-269A-4254-9925-3FD0DF134D56Q52937545-F81BE7B7-1DB8-4F41-9462-9F99203A4D09Q54991276-9D380ACD-9BF0-4B6B-B69F-3DA9D24E585DQ55150815-BFF2EC2F-D64C-498A-A117-59E0C6C88ABBQ55209742-804FD8FC-316A-4468-B47C-0BDACE1D1547Q56797729-A85B5557-A94B-45AF-BCEB-96513201047C
P2860
Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Active targeting of chemothera ...... nanoparticle-carrying T cells.
@en
type
label
Active targeting of chemothera ...... nanoparticle-carrying T cells.
@en
prefLabel
Active targeting of chemothera ...... nanoparticle-carrying T cells.
@en
P2093
P2860
P1476
Active targeting of chemothera ...... nanoparticle-carrying T cells.
@en
P2093
Bonnie Huang
Darrell J Irvine
Samantha S Luo
Sandra C Bustamante López
Wuhbet D Abraham
P2860
P304
P356
10.1126/SCITRANSLMED.AAA5447
P407
P50
P577
2015-06-01T00:00:00Z